Nebraska's fledgling medical cannabis program cleared a significant regulatory hurdle Tuesday when Attorney General Mike Hilgers issued a formal opinion finding that the state Medical Cannabis Commission's regulations do not clearly violate state or federal constitutional provisions. The regulations now move to Gov. Jim Pillen, who must act by July 11 to prevent a gap in the current temporary rules - set to expire July 15. For the small community of cultivators, manufacturers, and would-be dispensary operators watching this program take shape, the clock is running.
The constitutional sign-off doesn't resolve the deeper uncertainty hanging over the program, and operators would be right to read Hilgers' letter carefully rather than treat it as a clean bill of health. Hilgers made plain that his review carries no policy endorsement, and he flagged at least two live legal threats that could unwind the entire regulatory framework. Programs in more mature markets - including systems built to support point-of-sale for Massachusetts dispensaries - offer a reference point for what a functional licensed retail infrastructure looks like once regulatory stability settles in. Nebraska isn't there yet. What's striking here is that even the official tasked with confirming constitutionality went out of his way to attach conditions, caveats, and warnings to his own approval.
What the Regulations Actually Require
The Medical Cannabis Commission's formal regulations establish a tightly controlled framework - one that will shape the operational and economic reality of any licensed business attempting to build out in Nebraska. The constraints are significant, and any operator, investor, or vendor sizing up this market needs to understand what's on the table.
- Dispensary count is capped at 12 statewide, distributed by judicial district - meaning Douglas County (Omaha), Lancaster County (Lincoln), Sarpy/Cass Counties, and Buffalo/Hall Counties each get one dispensary, with the remaining eight slots spread across the rest of the state.
- Cultivators are limited to no more than 1,250 flowering plants at one time. Four cultivators have already been licensed - the maximum the regulations allow.
- Patient purchase limits are set at 5 ounces of medical cannabis per 30-day period from a single dispensary, with no more than 5 grams of delta-9 THC per transaction window.
- Smoking products, vaping products, and edibles of any kind are prohibited. Oral tablets with a thin flavoring layer to aid swallowing are permitted.
- Patients must access the system through a "Recommending Health Care Practitioner" directory - a structure advocates worry could sit nearly empty given the Legislature's failure to pass provider protections.
To put it plainly: this is a narrow program. The product category restrictions alone - no smokable flower, no vaping, no edibles - eliminate the highest-volume SKU categories that drive revenue in most adult-use and medical markets. For manufacturers and brands, that means a limited product set and a regulatory environment that doesn't reward broad catalog development. For dispensary operators, the economics will depend heavily on patient volume and the viability of the practitioner directory.
Two Legal Risks That Won't Go Away
Here's the catch. Hilgers' approval is explicitly conditional on circumstances that remain unresolved. He identified two distinct vectors of legal risk that operators, investors, and compliance professionals should treat as live variables - not background noise.
First, the Nebraska Supreme Court has not yet ruled on a challenge to whether the 2024 ballot initiative gathered enough valid signatures to be placed before voters. Oral arguments were heard in December 2024. As of the date of Hilgers' letter - more than 200 days later - no opinion has been issued. Hilgers stated directly: if the court finds the petition lacked sufficient valid signatures, the Nebraska Medical Cannabis Regulation Act would no longer be good law, and any regulations issued under it would lack statutory authority. That's an existential risk for the program, and it remains unresolved.
Second, Hilgers pointed to Nebraska's current exclusion from the federal congressional rider that has, since 2014, barred the use of federal funds to interfere with state-licensed medical cannabis programs. Forty-seven states are covered; Nebraska is not, because the program is still in early stages. Hilgers said he assumes Nebraska will eventually be added, but his constitutional clearance is predicated in part on that coverage existing. If it doesn't materialize - or if the federal regulatory environment shifts - the legal footing changes. Worth noting separately: Nebraska, under Hilgers, is also challenging the federal government's reclassification of state-licensed medical cannabis from Schedule I to Schedule III, a move that has meaningful implications for how federal law treats state programs.
What This Means for Operators Watching Nebraska
For any business considering a Nebraska license application - whether as a cultivator, manufacturer, transporter, or dispensary - the operational math is complicated by regulatory thinness on both the supply and retail sides. Four cultivators are licensed at the maximum cap. Manufacturer applications are open. Dispensary licenses, capped at 12, haven't been widely distributed yet. The patient access bottleneck - contingent on a practitioner directory that may struggle to attract providers - adds another layer of demand-side uncertainty.
The product restrictions also compress the revenue model in ways that don't apply in more permissive medical markets. Without edibles, smokable flower, or vaping products, operators are working with a constrained product menu. Oral tablets with flavoring to aid swallowing are allowed - but that's a narrow category, and it doesn't generate the retail traffic or basket size that a broader product assortment typically produces.
Advocates who backed the 2024 ballot initiative - which passed with roughly 71% of the vote - have been vocal about their concern that the regulatory structure, combined with Hilgers' ongoing legal opposition, could undermine the program's practical success before it reaches patients. That tension between voter intent and regulatory implementation is a familiar story in newer medical markets; it tends to resolve slowly, and not always in operators' favor.
The governor's decision in the coming days will determine whether the formal regulations take effect or whether the current emergency rules lapse. Either way, the Nebraska Supreme Court's pending opinion is the variable that matters most - and no one in this market can price that risk accurately until the court acts.
